ChemPartner PharmaTech Co.,Ltd. (SHE:300149)
China flag China · Delayed Price · Currency is CNY
10.01
+0.03 (0.30%)
At close: Sep 23, 2026

ChemPartner PharmaTech Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash & Equivalents
395.22411.83368.33347.26761.66160.46
Trading Asset Securities
12.8545.571.052.21-18.98
Cash & Short-Term Investments
408.07457.39369.37349.47761.66179.44
Cash Growth
8.49%23.83%5.70%-54.12%324.46%-35.73%
Accounts Receivable
263.71238.3199.01268.11349.87372.28
Other Receivables
7.226.9112.0612.0187.188.49
Receivables
270.94245.2211.07280.12437.06380.77
Inventory
17.89.4711.4427.8842.8268.81
Prepaid Expenses
4.234.770.8711.03--
Other Current Assets
55.2948.1851.3158.6838.8258.72
Total Current Assets
756.32765.02644.07727.181,280687.74
Property, Plant & Equipment
587.25617.45683.88851.39973.621,512
Long-Term Investments
186.03185.51214.46199.79197.02175.96
Goodwill
0.03--139.26858.861,207
Other Intangible Assets
32.3532.6930.6630.0555.66148.61
Long-Term Deferred Tax Assets
57.1246.7539.4640.4510.664.89
Long-Term Deferred Charges
217.53238.13267.09324.36370.23385.02
Other Long-Term Assets
151.24147.39116.18121.8577.4996.39
Total Assets
1,9882,0331,9962,4343,8244,218

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Accounts Payable
58.9650.3164.0253.7980.7108.38
Accrued Expenses
96.7199.8358.1982.78100.2690.66
Short-Term Debt
60.167.3258.4760115.02158.57
Current Portion of Long-Term Debt
9.098.286.524.3111.47330.13
Current Portion of Leases
57.8259.6373.9869.6367.2472.83
Current Income Taxes Payable
3.713.624.615.4249.858.6
Current Unearned Revenue
45.4746.5141.9377.2178.2657.59
Other Current Liabilities
14.4519.9538.9773.63129.24163.91
Total Current Liabilities
346.32355.45346.7426.77732.03990.66
Long-Term Debt
23.9628.9237.243.67177.21614.92
Long-Term Leases
274.01307.9337.13457.73495.25570.58
Long-Term Unearned Revenue
21.1223.4628.3627.4316.4120.47
Long-Term Deferred Tax Liabilities
3.083.32.8812.5812.0126.07
Other Long-Term Liabilities
13.713.575.475.245.025.81
Total Liabilities
682.18732.59757.75973.441,4382,229

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Common Stock
497.96497.96497.96499.78499.78499.78
Additional Paid-In Capital
1,2981,2601,2051,2291,2291,229
Retained Earnings
-528.5-497.51-510.92-284.45648.27269.68
Treasury Stock
----25.51-25.51-20.44
Comprehensive Income & Other
7.8315.9921.3317.649.81-13.76
Total Common Equity
1,2761,2761,2141,4372,3621,964
Minority Interest
29.9924.3424.224.2424.4324.63
Shareholders' Equity
1,3061,3001,2381,4612,3861,989
Total Liabilities & Equity
1,9882,0331,9962,4343,8244,218

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Total Debt
424.98472.04513.31635.34966.21,747
Net Cash (Debt)
-16.91-14.65-143.93-285.88-204.53-1,568
Net Cash Growth
------
Net Cash Per Share
-0.04-0.03-0.29-0.57-0.41-3.16
Filing Date Shares Outstanding
504.99497.96497.96497.96497.96498.33
Total Common Shares Outstanding
497.96497.96497.96497.96497.96498.33
Working Capital
410409.57297.37300.4548.33-302.91
Book Value Per Share
2.562.562.442.894.743.94
Tangible Book Value
1,2431,2431,1831,2671,447608.37
Tangible Book Value Per Share
2.502.502.382.552.911.22
Buildings
102.02102.02102.02103.152.82238.54
Machinery
645.5623.63609.96554.12464.19791.09
Construction In Progress
9.974.07137.9675.36235.74